USP订购编号 |
美国药典,USP分析标准品,英文名称,规格 |
CAS编号查询 |
UN编号对照 |
USP-1062020 |
Benzyl Disulfide (200 mg) |
150-60-7 |
|
2930902000 |
|
|
|
USP-1065209 |
Berberis aristata Stem Dry Extract (100 mg) |
NA |
|
1302190200 |
|
|
|
USP-1065210 |
Berberine Chloride (50 mg) |
141433-60-5 |
|
2939790000 |
|
|
|
USP-1065221 |
Bendamustine Hydrochloride (200 mg) |
3543-75-7 |
UN2811 |
USP-1065232 |
Bendamustine Related Compound A (25 mg) (4-{5-[Bis(2-hydroxyethyl)amino]-1-methyl-1H-benzimidazol-2-yl}butanoic acid hydrochloride) |
109882-29-3 |
|
2933998350 |
|
|
|
USP-1065243 |
Bendamustine Related Compound B (20 mg) (4-(1-Methyl-5-morpholino-1H-benzimidazol-2-yl)butanoic acid hydrochloride) |
N/A |
|
2934990005 |
|
|
|
USP-1065254 |
Bendamustine Related Compound C (20 mg) (Ethyl 4-{5-[bis(2-hydroxyethyl)amino]-1-methyl-1H -benzimidazol-2-yl}butanoate) |
3543-74-6 |
|
2933998350 |
|
|
|
USP-1065265 |
Bendamustine Related Compound D (20 mg) (4-{5-[(2-Chloroethyl)amino]-1-methyl-1H -benzimidazol-2-yl}butanoic acid hydrochloride) |
1797881-48-1 |
|
2933998350 |
|
|
|
USP-1065276 |
Bendamustine Related Compound E (20 mg) (4-{5-[(2-Chloroethyl)(2-hydroxyethyl)amino]-1-methyl-1H-benzimidazol-2-yl}butanoic acid) |
109882-27-1 |
|
2933997500 |
|
|
|
USP-1134288 |
Citalopram Related Compound E (25 mg) (1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile-N-oxide hydrochloride) |
62498-71-9 |
|
2932996560 |
|
|
|
USP-1134299 |
Citalopram Related Compound F (200 mg) (dimethyl-(1-methyl-3,3-diphenyl-allyl)-amine hydrochloride) |
55011-89-7 |
UN2811 |
USP-1134305 |
Citicoline Sodium (2 x 350 mg) |
33818-15-4 |
|
2934990005 |
|
|
|
USP-1134313 |
Ciprofloxacin (200 mg) |
85721-33-1 |
UN3077 |
USP-1134324 |
Ciprofloxacin Ethylenediamine Analog (25 mg) (1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[(2-aminoethyl)amino]-3-quinolinecarboxylic acid hydrochloride) |
528851-31-2 |
|
2933497050 |
|
|
|
USP-1152600 |
Cyclamic Acid (100 mg) |
100-88-9 |
|
2929909000 |
|
|
|
USP-1152701 |
Cyclandelate (200 mg) |
456-59-7 |
|
2918191350 |
|
|
|
USP-1152814 |
Cyclic Olefin Polymer (1 g) |
N/A |
|
3902900050 |
|
|
|
USP-1154004 |
Cyclizine Hydrochloride (200 mg) |
303-25-3 |
UN2811 |
USP-1154503 |
Cyclobenzaprine Hydrochloride (200 mg) |
6202-23-9 |
|
2921490002 |
|
|
|
USP-1235106 |
Emtricitabine (200 mg) |
143491-57-0 |
|
2934990005 |
|
|
|
USP-1235128 |
Emtricitabine System Suitability Mixture A (15 mg) |
N/A |
|
2934990005 |
|
|
|
USP-1235139 |
Emtricitabine System Suitability Mixture B (15 mg) |
N/A |
|
3822190000 |
|
|
|
USP-1235240 |
Emulsifying Wax (30 mg) |
N/A |
|
3404200000 |
|
|
|
USP-1235274 |
Enalaprilat (300 mg) |
84680-54-6 |
|
2933995300 |
|
|
|
USP-1235300 |
Enalapril Maleate (200 mg) |
76095-16-4 |
|
2933995300 |
|
|
|
USP-1235332 |
Enalapril Related Compound D (25 mg) ((S)-Ethyl 2-[(3S,8aS)-3-methyl-1,4-dioxohexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-4-phenylbutanoate) |
115729-52-7 |
|
2933790002 |
|
|
|
USP-1235365 |
Enalapril Related Compound H (25 mg) (1-{N-[(S)-1-Ethoxycarbonyl-3-cyclohexylpropyl]-L-alanyl}-L-proline, maleate (1:1)) |
n/a |
|
2933999552 |
|
|
|
USP-1236700 |
(-)-Epigallocatechin-3-O-gallate (20 mg) |
989-51-5 |
|
2932996560 |
|
|
|
USP-1236801 |
Epilactose (200 mg) |
50468-56-9 |
|
2940006000 |
|
|
|
USP-1236833 |
Lovastatin Epimer Mixture (25 mg) (Epilovastatin and Lovastatin 1:1 Mixture) |
N/A |
|
2932206000 |
|
|
|
USP-1236889 |
Epinastine Hydrochloride (250 mg) |
108929-04-0 |
UN2811 |
USP-1236890 |
Epinastine Related Compound A (25 mg) ((6,11-Dihydro-5H-dibenzo[b,e]azepin-6-yl)methanamine fumarate) |
127785-96-0 |
|
2933992600 |
|
|
|
USP-1236970 |
Epinephrine (200 mg) |
51-43-4 |
UN2811 |
USP-1237000 |
Epinephrine Bitartrate (200 mg) |
51-42-3 |
UN2811 |
USP-1237382 |
Epirubicin Hydrochloride (200 mg) |
56390-09-1 |
|
2941906000 |
|
|
|
USP-1237553 |
Eplerenone (250 mg) |
107724-20-9 |
|
2932202000 |
|
|
|
USP-1237622 |
Epoprostenol Related Compound B (15 mg) (Sodium 5-(diphenylphosphinoyl)pentanoate) |
N/A |
|
2937500000 |
|
|
|
USP-1238002 |
Equilin (25 mg) |
474-86-2 |
|
2937230000 |
|
|
|
USP-1238217 |
Eprosartan Mesylate (50 mg) ((E)-2-Butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid, monomethanesulfonate) |
144143-96-4 |
|
2934990005 |
|
|
|
USP-1238228 |
Eprosartan Related Compound A (20 mg) ((E)-3-(2-butyl-1H-imidazol-5-yl)-2-(thiophen-2-ylmethyl)acrylic acid hydrochloride) |
N/A |
|
2934990005 |
|
|
|
USP-1238239 |
Eprosartan Related Compound B (15 mg) (3-(thiophen-2-yl)propanoic acid) |
5928-51-8 |
UN3261 |
USP-1238240 |
Eprosartan Related Compound C (25 mg) (2-(thiophen-2-ylmethyl)malonic acid) |
4475-24-5 |
|
2934990005 |
|
|
|
USP-1238251 |
Eprosartan Related Compound D (15 mg) (4-(bromomethyl)benzoic acid) |
6232-88-8 |
UN3261 |
USP-1238262 |
Eprosartan Related Compound E (15 mg) (4-(hydroxymethyl)benzoic acid) |
3006-96-0 |
|
2918992090 |
|
|
|
USP-1238512 |
Beta-3-Asp Eptifibatide (10 mg) (N6-Amidino-N2-(3-mercaptopropionyl)-L-lysylglycyl-L-Beta-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide) |
NA |
|
2934990005 |
|
|
|
USP-1238523 |
D-Har Eptifibatide (10 mg) (N6-Amidino-N2-(3-mercaptopropionyl)-D-lysylglycyl-D-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide) |
NA |
|
2934990005 |
|
|
|
USP-1238556 |
3-D-Asp Eptifibatide (10 mg) (N6-Amidino-N2-(3-mercaptopropionyl)-L-lysylglycyl-D-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide) |
NA |
|
2934990005 |
|
|
|
USP-1238578 |
6-D-Cys Eptifibatide (10 mg) (N6-Amidino-N2-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-D-cysteinamide, cyclic(1-6)-disulfide) |
NA |
|
2934990005 |
|
|
|
USP-1239504 |
Ergoloid Mesylates (300 mg) |
8067-24-1 |
|
3003490000 |
|
|
|
USP-1241007 |
Ergosterol (50 mg) |
57-87-4 |
UN2811 |
USP-1241550 |
Ergotaminine (100 mg) |
639-81-6 |
|
2939690000 |
|
|
|
USP-1241608 |
Erlotinib Hydrochloride (150 mg) |
183319-69-9 |
|
2933595960 |
|
|
|
USP-1269232 |
Famotidine Related Compound C (25 mg) (3-[[2-(Diaminomethyleneamino)thiazol-4-yl]methylthio]-N-sulfamoylpropanamide hydrochloride) |
76824-17-4 |
|
2934100000 |
|
|
|
USP-1269243 |
Famotidine Related Compound D (25 mg) (3-[[2-(diaminomethyleneamino)thiazol-4-yl]methylthio]propanamide) |
76824-16-3 |
|
2934990005 |
|
|
|
USP-1349740 |
Methoxsalen Related Compound B (25 mg) (4,9-Dimethoxy-7H-furo[3,2-g]chromen-7-one) |
482-27-9 |
|
2932202000 |
|
|
|
USP-1359415 |
Levetiracetam Racemic Mixture (15 mg) (1:1 mixture of levetiracetam S-enantiomer-(2S)-2-(2-oxopyrrolidin-1-yl)butanamide and levetiracetam R-enantiomer (2R)-2-(2-oxopyrrolidin-1-yl)butanamide) |
33996-58-6 |
|
2933790002 |
|
|
|
USP-1359426 |
Levetiracetam Related Compound A (20 mg) ((S)-N-(1-amino-1-oxobutan-2-yl)-4-chlorobutanamide) |
102767-31-7 |
|
2924190002 |
|
|
|
USP-1359437 |
Levetiracetam Related Compound B (20 mg) ((S)-2-aminobutanamide hydrochloride) |
7682-20-4 |
|
2924190002 |
|
|
|
USP-1359801 |
Levobunolol Hydrochloride (200 mg) |
27912-14-7 |
|
2922504500 |
|
|
|
USP-1359856 |
Levocabastine Hydrochloride (50 mg) |
79547-78-7 |
|
2933399095 |
|
|
|
USP-1359867 |
Levocabastine Related Compound A (50 mg) (1-[cis-4-cyano-4-(4-fluorophenyl)cyclohexyl]-4-phenylpiperidine-4-carboxylic acid hydrochloride) |
80139-91-9 |
|
2933399095 |
|
|
|
USP-1359903 |
Levocarnitine (400 mg) |
541-15-1 |
|
2923900100 |
|
|
|
USP-1370360 |
Lorazepam Related Compound E (25 mg) (6-Chloro-4-(o-chlorophenyl)-2-quinazoline methanol) |
773871-49-1 |
|
2933998350 |
|
|
|
USP-1370462 |
Losartan Potassium (150 mg) |
124750-99-8 |
|
2933290000 |
|
|
|
USP-1370473 |
Losartan Related Compound A (20 mg) (2-Butyl-4-chloro-1H-imidazole-5-carbaldehyde) |
83857-96-9 |
UN3077 |
USP-1370484 |
Losartan Related Compound B (20 mg) (2-Butyl-4-chloro-(1-{[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methyl acetate) |
1006062-27-6 |
|
2933290000 |
|
|
|
USP-1370495 |
Losartan Related Compound C (20 mg) (2-Butyl-4-chloro-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-imidazol-5-carbaldehyde) |
114798-36-6 |
|
2933290000 |
|
|
|
USP-1370509 |
Losartan Related Compound D (20 mg) (5-[4′-({2-Butyl-5-[(5-{4′-[(2-butyl-4-chloro-5-hydroxymethyl-1H-imidazol-1-yl)methyl]biphenyl-2-yl}-1H-tetrazol-1-yl)methyl]-4-chloro-1H-imidazol-1-yl}methyl)biphenyl-2-yl]tetrazol, potassium salt) |
N/A |
|
2933290000 |
|
|
|
USP-1370510 |
Losartan Related Compound E (20 mg) (5-[4′-({2-Butyl-5-[(5-{4′-[(2-butyl-4-chloro-5-hydroxymethyl-1H-imidazol-1-yl)methyl]biphenyl-2-yl}-2H-tetrazol-2-yl)methyl]-4-chloro-1H-imidazol-1-yl}methyl)biphenyl-2-yl]tetrazol, potassium salt) |
N/A |
|
2933290000 |
|
|
|
USP-1370600 |
Lovastatin (125 mg) |
75330-75-5 |
|
2932206000 |
|
|
|
USP-1370611 |
Lovastatin Related Compound A (20 mg) (4,4a-Dihydrolovastatin) |
N/A |
|
2933997500 |
|
|
|
USP-1370655 |
Lovastatin Impurity Identification Mixture (30 mg) |
N/A |
|
3822190000 |
|
|
|
USP-1370688 |
Low-substituted Carboxymethylcellulose Sodium (100 mg) |
9004-32-4 |
|
3912310000 |
|
|
|
USP-1370699 |
Loxapine N-Oxide (25 mg) (4-(2-Chlorodibenzo[b,f][1,4]oxazepin-11-yl)-1-methylpiperazine 1-oxide) |
25967-34-4 |
|
2934990005 |
|
|
|
USP-1370702 |
Loxapine Succinate (125 mg) |
27833-64-3 |
UN2811 |
USP-1370713 |
Loxapine Related Compound A (20 mg) (3-Chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine) |
3454-96-4 |
|
2934990005 |
|
|
|
USP-1370724 |
Lufenuron Related Compound B (15 mg) (N-[(2,5-Dichloro-4-hydroxyphenyl)carbamoyl]-2,6-difluorobenzamide) |
N/A |
|
2924210000 |
|
|
|
USP-1370735 |
Lufenuron Related Compound C (15 mg) (N-[3-Chloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenylcarbamoyl]-2,6-difluorobenzamide) |
N/A |
|
2924210000 |
|
|
|
USP-1370746 |
Lumefantrine (100 mg) |
82186-77-4 |
|
2922190900 |
|
|
|
USP-1370757 |
Lumefantrine Related Compound A (25 mg) ((RS, Z)-2-(Dibutylamino)-2-(2,7-dichloro-9-(4-chlorobenzylidene)-9H-fluoren-4-yl)ethanol hydrochloride) |
NA |
|
2922199695 |
|
|
|
USP-1437020 |
Methylprednisolone Hemisuccinate Related Compound B (50 mg) (11Beta,21-Dihydroxy-6alpha-methyl-3,20-dioxopregna-1,4-dien-17-yl hydrogen succinate) |
77074-42-1 |
|
2918992090 |
|
|
|
USP-1437042 |
Methylprednisolone Hemisuccinate Related Compound D (50 mg) (11Beta,17-Dihydroxy-6alpha-methyl-3,20-dioxopregna-4-en-21-yl hydrogen succinate) |
119657-85-1 |
|
2937290000 |
|
|
|
USP-1437461 |
Methyl Salicylate Related Compound A (50 mg) (Dimethyl 4-hydroxyisophthalate) |
5985-24-0 |
|
2918230000 |
|
|
|
USP-1437508 |
Methyl Stearate (300 mg) |
112-61-8 |
|
2915700100 |
|
|
|
USP-1437600 |
Methylsulfonylmethane (200 mg) |
67-71-0 |
|
2930909265 |
|
|
|
USP-1437701 |
Terbinafine Related Compound D (25 mg) ((2E)-N,6,6-trimethyl-N-[(4-methylnaphthalen-1-yl)methyl]-hept-2-en-4-yn-1-amine hydrochloride) |
877265-33-3 |
|
2921490002 |
|
|
|
USP-1438205 |
Methyl Tricosanoate (200 mg) (Tricosanoic acid, methyl ester) |
2433-97-8 |
|
2915900000 |
|
|
|
USP-1438318 |
5-O-Methylvisammioside (25 mg) |
84272-85-5 |
|
2938900000 |
|
|
|
USP-1448967 |
Mycophenolate Mofetil Related Compound A (15 mg) (2-Morpholinoethyl (E)-6-(1,3-dihydro-4,6-dihydroxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate) |
1322681-36-6 |
|
2934990005 |
|
|
|
USP-1448978 |
Mycophenolate Mofetil Related Compound B (15 mg) [(RS)-7-hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3H-isobenzofuranyl-1-one] |
26675-76-3 |
|
2932206000 |
|
|
|
USP-1448989 |
Mycophenolate Sodium (200 mg) |
37415-62-6 |
UN3077 |
USP-1448990 |
Myristic Acid (200 mg) |
544-63-8 |
|
2915900000 |
|
|
|
USP-1449008 |
Myristyl Alcohol (5 x 100 mg) |
112-72-1 |
|
2905199095 |
|
|
|
USP-1449041 |
Myristylpyridinium Chloride (25 mg) (1-Tetradecylpyridinium chloride) |
2785-54-8 |
UN2811 |
USP-1449518 |
Nabumetone (200 mg) |
42924-53-8 |
|
2914500000 |
|
|
|
USP-1449530 |
Nabumetone Related Compound A (15 mg) (1-(6-methoxy-2-naphthyl)-but-1-en-3-one) |
127053-22-9 |
|
2914500000 |
|
|
|
USP-1449700 |
Nadolol (200 mg) |
42200-33-9 |
|
2922190900 |
|
|
|
USP-1449711 |
Nadolol Related Compound A (25 mg) ((2RS,3SR)-5-(2,3-Dihydroxypropoxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol) |
N/A |
|
2909500000 |
|
|
|
USP-1449722 |
Nadolol Related Compound B (25 mg) ((2RS,3SR)-5-(2-Hydroxy-3-methoxypropoxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol) |
N/A |
|
2909490000 |
|
|
|
USP-1449733 |
Nadolol Related Compound C (25 mg) |
N/A |
|
2909490000 |
|
|
|
USP-1449766 |
Nadolol Related Compound F (25 mg) (1-(tert-Butylamino)-3-(naphthalen-1-yloxy)propan-2-ol) |
2116-22-5 |
|
2922199695 |
|
|
|
USP-1449777 |
Nadolol Related Compound G (25 mg) (1-(tert-Butylamino)-3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propan-2-ol) |
33841-03-1 |
|
2922199695 |
|
|
|
USP-1450007 |
Nafcillin Sodium (200 mg) |
7177-50-6 |
|
2941106000 |
|
|
|
USP-1605500 |
Ropivacaine Hydrochloride (200 mg) |
132112-35-7 |
|
2933399095 |
|
|
|
USP-1605512 |
Ropivacaine Related Compound A (25 mg) (2,6-dimethylaniline hydrochloride) |
21436-98-6 |
|
2921490002 |
|
|
|
USP-1605523 |
Ropivacaine Related Compound B (50 mg) ((R)-N-(2,6-Dimethylphenyl)-1-propylpiperidine-2-carboxamide hydrochloride monohydrate) |
N/A |
|
2933399095 |
|
|
|
USP-1605588 |
Rosavin (25 mg) ((2E)-3-Phenylprop-2-en-1-yl 6-O-alpha-l-arabinopyranosyl-Beta-D-glucopyranoside) |
84954-92-7 |
|
2939790000 |
|
|
|
USP-1605668 |
Powdered Rosemary Extract (1 g) |
84604-14-8 |
|
1302190200 |
|
|
|
USP-1605680 |
Powdered Rosemary Hydrophilic Extract (1 g) |
84604-14-8 |
|
1302190200 |
|
|
|
USP-1605817 |
Rosiglitazone Maleate (200 mg) |
122320-73-4 |
|
2934100000 |
|
|
|
USP-1605828 |
Rosiglitazone Related Compound A (25 mg) ((5Z)-5-{[4-({2-[methyl(2-pyridinyl)amino]ethyl}oxy)phenyl]methylidene}-1,3-thiazolidine-2,4-dione) |
160596-25-8 |
|
2934100000 |
|
|
|
USP-1605952 |
Rosmarinic Acid (25 mg) |
20283-92-5 |
|
2918992090 |
|
|
|
USP-1606004 |
Rosuvastatin System Suitability Mixture (15 mg) (A mixture containing rosuvastatin calcium, rosuvastatin ketone, rosuvastatin lactone and rosuvastatin diastereomers.) |
N/A |
|
3822190000 |
|
|
|